Reported Earlier, Pliant Therapeutics Presented Bexotegrast Program Data At American Thoracic Society 2024 International Conference
Portfolio Pulse from Benzinga Newsdesk
Pliant Therapeutics presented data on their bexotegrast program at the American Thoracic Society 2024 International Conference. The data showed that bexotegrast was well tolerated across multiple studies, including Phase 1 and Phase 2 trials, with most adverse events being mild to moderate.
May 22, 2024 | 7:51 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pliant Therapeutics presented positive safety and tolerability data for bexotegrast at a major conference, which could boost investor confidence and positively impact the stock price in the short term.
The presentation of positive safety and tolerability data for bexotegrast at a major conference is likely to increase investor confidence in Pliant Therapeutics, potentially leading to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100